Octreotide Acetate

Teva Pharmaceuticals USA, Inc. has initiated a Class II recall of Octreotide Acetate for Injectable Suspension, impacting 2,200 kits nationwide. This action stems from FDA inspection findings at contract manufacturer Pharmathen International S.A. in Greece, revealing critical quality system deficiencies affecting sterility assurance. Procurement and supply chain leaders must assess immediate supply risks and diversify sourcing strategies.

Teva Pharmaceuticals USA, Inc. has initiated a nationwide Class II recall of 21,930 cartons of Octreotide Acetate for Injectable Suspension. This critical action stems from a lack of sterility assurance identified during an FDA inspection at its contract manufacturer, Pharmathen International S.A. in Greece, highlighting significant quality system deficiencies impacting patient safety and supply chain integrity.

Teva Pharmaceuticals USA, Inc. has initiated a Class II recall for 19,869 cartons of Octreotide Acetate for Injectable Suspension. This action stems from critical sterility assurance deficiencies identified by the FDA at its contract manufacturer, Pharmathen International S.A. in Greece. Procurement and regulatory teams must assess supply chain vulnerabilities and review quality oversight protocols for sterile injectables.